BC Innovations | Apr 4, 2013
Cover Story

Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylase s, 1 a not-so-well-understood subset of the target family that...
BC Innovations | Jun 2, 2011
Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Histone deacetylase 4 (HDAC4); HDAC5; HDAC7 A study in mice suggests antagonizing the class IIa HDACs-HDAC4, HDAC5 and HDAC7-could help treat type...
BC Innovations | Oct 21, 2010
Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Muscular atrophy Histone deacetylase 4 (HDAC4); HDAC5 Studies in mice suggest that inhibiting HDAC4 or HDAC5 could help treat neurogenic muscular atrophy. In a...
BC Innovations | Oct 21, 2010
Targets & Mechanisms

Unnerving atrophy

A team at The University of Texas Southwestern Medical Center at Dallas has shown that deletion of class IIa histone deacetylases prevents muscle atrophy after nerve damage. 1 The result suggests that inhibitors of these...
BC Innovations | Feb 5, 2009
Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/ marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiac hypertrophy; cardiac fibrosis Calcium calmodulin-dependent protein kinase II (CAMK2) Studies in mice suggest that targeting CAMK2 could...
BC Innovations | Aug 21, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cardiovascular disease Left ventricular hypertrophy (LVH) G protein-coupled receptor kinase 5 (GRK5); G protein q polypeptide (GNAQ) (G-ALPHA-q); histone deacetylase 5...
BC Innovations | Aug 21, 2008
Targets & Mechanisms

GRK5: Big-hearted Target

A team of U.S. and U.K. researchers has uncovered a new role for G protein-coupled receptor kinase 5 in pathological cardiac hypertrophy, providing a first mechanistic target for this indication. 1 It behaves more like...
Items per page:
1 - 7 of 7